Enhancing monoclonal antibody production efficiency using CHO-MK cells and specific media in a conventional fed-batch culture
- PMID: 39568575
- PMCID: PMC11573942
- DOI: 10.1007/s10616-024-00669-4
Enhancing monoclonal antibody production efficiency using CHO-MK cells and specific media in a conventional fed-batch culture
Abstract
Chinese hamster ovary (CHO) cell lines, derived as subclones from the original CHO cell line, are widely used hosts for current biopharmaceutical productions. Recently, a highly proliferative host cell line, CHO-MK, was established from the Chinese hamster ovary tissue. In this study, we assessed the fundamental culture characteristics and capabilities of CHO-MK cells for monoclonal antibody (mAb) production using specified chemically defined media. To achieve this, we established fed-batch cultures of model CHO-MK cells in shake flasks and ambr15 and 2 L bioreactors under various conditions. The mAb-producing CHO-MK cell line A produced 12.6 g/L of antibody within 7 days in the fed-batch culture using a 2 L bioreactor, with a seeding density of 1 × 106 cells/mL. This performance corresponded to a space-time yield of 1.80 g/L/day, representing a productivity level that could be challengingly attained in fed-batch cultures using conventional CHO cells. In addition, when we subjected six different mAb-producing CHO-MK cell lines to fed-batch culture in the ambr15 bioreactor for 7 days, the antibody production ranged between 5.1 and 10.8 g/L, confirming that combining CHO-MK cells and specified media leads to enhanced versatility. These discoveries underscore that CHO-MK cells combined with specified media might represent a next-generation production platform, which could potentially respond to an increasing demand for antibody drugs, reducing production costs, and shortening antibody drug development times. This study is expected to serve as a benchmark for future production process development using CHO-MK cells.
Keywords: CHO-MK; Chemically defined media; Fed-batch culture; Monoclonal antibody production; Space–time yield.
© The Author(s), under exclusive licence to Springer Nature B.V. 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Conflict of interest statement
Conflict of interestThe authors declare no competing interests.
Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
An automated high inoculation density fed-batch bioreactor, enabled through N-1 perfusion, accommodates clonal diversity and doubles titers.Biotechnol Prog. 2024 Mar-Apr;40(2):e3410. doi: 10.1002/btpr.3410. Epub 2023 Nov 28. Biotechnol Prog. 2024. PMID: 38013663
-
Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchange.Biotechnol Prog. 2024 May-Jun;40(3):e3435. doi: 10.1002/btpr.3435. Epub 2024 Feb 8. Biotechnol Prog. 2024. PMID: 38329375
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Eliciting adverse effects data from participants in clinical trials.Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2. Cochrane Database Syst Rev. 2018. PMID: 29372930 Free PMC article.
Cited by
-
Process mapping and optimization study of CHO cell cultures for mAb production using Ambr® 250 high-throughput parallel bioreactors.Bioprocess Biosyst Eng. 2025 Aug 30. doi: 10.1007/s00449-025-03229-y. Online ahead of print. Bioprocess Biosyst Eng. 2025. PMID: 40884591
-
Process development for production of non-originator NISTmAb from CHO and NS0 cell lines.MAbs. 2025 Dec;17(1):2505088. doi: 10.1080/19420862.2025.2505088. Epub 2025 May 22. MAbs. 2025. PMID: 40405416 Free PMC article.
References
-
- Ali AS, Raju R, Kshirsagar R, Ivanov AR, Gilbert A, Zang L, Karger BL (2019) Multi-omics study on the impact of cysteine feed level on cell viability and mAb production in a CHO bioprocess. Biotechnol J 14(4):e1800352. 10.1002/biot.201800352 - PubMed
-
- Ali AS, Chen R, Raju R, Kshirsagar R, Gilbert A, Zang L, Karger BL, Ivanov AR (2020) Multi-omics reveals impact of cysteine feed concentration and resulting redox imbalance on cellular energy metabolism and specific productivity in CHO cell bioprocessing. Biotechnol J 15(8):e1900565. 10.1002/biot.201900565 - PMC - PubMed
-
- Bielser JM, Wolf M, Souquet J, Broly H, Morbidelli M (2018) Perfusion mammalian cell culture for recombinant protein manufacturing—a critical review. Biotechnol Adv Jul-Aug 36(4):1328–1340. 10.1016/j.biotechadv.2018.04.011 - PubMed
-
- Bryan L, Clynes M, Meleady P (2021) The emerging role of cellular post-translational modifications in modulating growth and productivity of recombinant Chinese hamster ovary cells. Biotechnol Adv Jul-Aug 49:107757. 10.1016/j.biotechadv.2021.107757 - PubMed
LinkOut - more resources
Full Text Sources